Is the end of chronic hepatitis C virus infection in sight?
Geoffrey W
GW
McCaughan
D000998:Antiviral Agents / Q000627:therapeutic use*; D055030:Drug Users; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008954:Models, Biological; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*; D015819:Substance Abuse, Intravenous / Q000150:complications*
D000998:Antiviral Agents; D016898:Interferon-alpha; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a